Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus (albumin-bound) + Palbociclib + Fulvestrant in Advanced HR+/HER2- Breast Cancer
NCT06856200Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Oct 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-sirolimus in breast cancer, sponsored by Fudan University. Primary endpoints: Adverse Events, Dose-Limiting Toxicities and 2 more. Started Feb 2025; status: recruiting.
02
Drugs
nab-sirolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06856200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06856200.